Outstanding

Standing out with
our products.
We possess a broad portfolio of more than
70 commercial products that address patient
needs across five core therapeutic fields
which include urology, endocrinology, pain
management, allergy and women’s health.
We continue to explore the category para meters
in search of the right product for the right
indication at the right price.
Our strategy is to leverage our strong sales and
marketing capabilities to enhance the performance of
existing and newly acquired pharmaceutical products.
Our sales and marketing team provides targeted
promotion for our inno vative products in these five
core therapeutic fields. By focusing on specialty
pharmaceuticals we are able to aggressively capitalize
on market opportunities that may be under-served by
large pharmaceutical companies.
Our product acquisition process screens and
selects candidates based on a defined set of
criteria that includes product differentiation
from existing com mercial pharmaceuticals and
the potential to complement our existing pipeline.
A new way to treat pain.
Tridural® is indicated for moderately severe pain. Some of the benefits include: Initial rapid release,
rapid titration, efficacious analgesia sustained for 24 hours and favourable safety profile.
A better way to manage prostate cancer.
Trelstar®, injectable luteinizing hormone-releasing agonist (LHRH), bolster both our urology and women’s
health franchises as they are indicated for the palliative treatment of prostate cancer and endometriosis.
Improving access to emergency contraceptive pills for Canadian women.
PLAN B® is a safe and effective emergency contraceptive and is now available over-the-counter.
Most Canadian women have access to emergency contraception without having to talk to a doctor
or physician.
5